logo
logo
CORT stock ticker logo

Corcept Therapeutics Incorporated

NASDAQ•CORT
CEO: Dr. Joseph K. Belanoff M.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2004-04-14
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
Contact Information
149 Commonwealth Drive, Menlo Park, CA, 94025, United States
650-327-3270
www.corcept.com
Market Cap
$3.59B
P/E (TTM)
35.4
17.4
Dividend Yield
--
52W High
$117.33
52W Low
$28.66
52W Range
6%
Rank20Top 6.4%
6.1
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Strong • 6.1 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$202.13M+0.00%
4-Quarter Trend

EPS

$0.24+0.00%
4-Quarter Trend

FCF

$38.40M+0.00%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Strong Product Revenue Growth Net product revenue reached $761.4M in 2025, driven by 37.0% sales volume increase despite authorized generic launch.
Significant R&D Investment R&D expense totaled $254.9M for 2025, reflecting advancement across oncology, ALS, and metabolic pipeline programs.
Robust Liquidity Position Cash and marketable securities totaled $532.4M as of December 31, 2025, supporting operations and development plans.

Risk Factors

Relacorilant Approval Delayed FDA issued Complete Response Letter in December 2025 for hypercortisolism NDA, requiring additional evidence of efficacy.
Increased Operating Expenses SG&A expenses surged to $448.7M in 2025, partially offsetting revenue gains and reducing net income to $99.7M.
Generic Competition Pressure Teva patent litigation loss affirmed in February 2026; generic Korlym availability pressures pricing and revenue potential.
Pharmacy Vendor Transition Risk Transition from Optime to Curant in late 2025 risked supply disruptions, impacting ability to meet full product demand.

Outlook

Pursuing Relacorilant Path Working with FDA to determine optimal path for relacorilant approval following the recent Complete Response Letter.
Oncology NDA PDUFA Date NDA for relacorilant plus nab-paclitaxel in ovarian cancer has PDUFA date of July 11, 2026, with EMA review ongoing.
Pipeline Trial Expansion Initiated Phase 2 trials (BELLA, TRIDENT, STELLA) evaluating relacorilant and nenocorilant across oncology and ALS indications.
Funding Operations Internally Expect to fund planned R&D activities over next 12 months and beyond without needing to raise additional external funds.

Peer Comparison

Revenue (TTM)

JAZZ stock ticker logoJAZZ
$4.27B
+4.9%
HALO stock ticker logoHALO
$1.40B
+37.6%
CORT stock ticker logoCORT
$761.41M
+12.8%

Gross Margin (Latest Quarter)

CORT stock ticker logoCORT
98.7%
-0.6pp
JAZZ stock ticker logoJAZZ
97.9%
-12.3pp
MRUS stock ticker logoMRUS
94.7%
+55.6pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
RVMD$19.74B-16.7-63.1%6.7%
JAZZ$11.42B-31.8-8.8%46.4%
AXSM$8.16B-44.1-254.1%35.0%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
8.7%
Steady Growth
4Q Net Income CAGR
6.2%
Profitability Improving
Cash Flow Stability
100%
Strong Cash Flow

Deep Research

Next earnings:May 4, 2026
|
EPS:-$0.11
|
Revenue:$186.61M
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data